GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, announced today that it has been awarded three U.S. patents covering the company's core proprietary calibration technique and sensor membrane.
GlySure's CBGM system comprises two main parts, a monitor and a sterile sensor set, which includes an integrated fiber-optic sensor/introducer and a fully automated calibration module. The sensor is shipped connected to the calibration module which performs a fully automated three point calibration prior to use. Two of the patents (8,607,612 and 8,746,031) are related to this calibration technique, which helps ensure the accuracy and performance of the system.
The third patent, granted pending number assignment, covers the company's sensor membrane, which facilitates accurate performance over long periods of time by preventing interferences from reaching the sensor's fluorescent indicator chemistry. In clinical testing on intensive care patients, clinicians have used the sensor to continuously monitor patients throughout their length of stay (over 150 hours).
"The addition of these three new patents brings our total number of granted patents to 14 and considerably strengthens the company's intellectual property," said GlySure's Chief Technical Officer Barry Crane. "We've designed our system to address the specific needs of the intensive care unit (ICU), including the demanding ICU environment, work patterns of ICU clinicians and the critically ill nature of ICU patients. Based on the results of our research, we are very pleased with the performance of our system and its ability to deliver accurate continuous blood glucose readings across a broad range of critically ill ICU patients."
Omega-3s in the spotlight: The impact of EPA and DHA on athlete health and performance